Clinical Trial Update: Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases [Phase 2]

View source ↗

Summary

This Phase 2 trial update evaluates docetaxel with or without imatinib mesylate in patients with androgen-independent (castration-resistant) prostate cancer and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Cancer, Prostate Cancer | Phase 2 | Status: COMPLETED